CClinicalTrials.gg
CompletedNCT05948683PEMUpdated Aug 19, 2024

Prosocial Effects of MDMA

An Early Phase 1 interventional study of MDMA and Placebo in MDMA ('Ecstasy') and Social Interaction, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by University of Chicago · Early Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 2 months ago, and no results have been posted to the registry.
Phase
Early Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person

Read the detailed description

MDMA has shown promise as an adjunct to psychotherapy in the treatment of PTSD and other disorders. When used clinically with psychotherapy, the drug is believed to interact with the interpersonal components of the psychotherapy, especially the patient-therapist interaction. Indeed, patients and therapists usually form a strong alliance during several preparatory sessions, even before a drug is administered. Experts believe that the patient's familiarity and trust of the therapist is critical to the success of the intervention. Whereas therapeutic alliance is critical to the success of any psychotherapy, it may be especially important when psychoactive drugs are part of the treatment. The importance of this trust-building component preceding drug-assisted therapy has not been investigated.

There are mechanistic reasons to expect that MDMA will be more effective when a patient interacts with a familiar and trusted other person, compared to a stranger. MDMA is thought to exert its "prosocial" effects by increasing the social bonding hormone, oxytocin, and this hormone may contribute to its therapeutic effects. However, there is evidence that oxytocin increases feelings of connectedness specifically with familiar "in-group" members, and that it may not produce affiliative effects with individuals who are unfamiliar, or perceived to be outside their groups. Thus, the pro-social effects of oxytocin may depend on the degree of familiarity and closeness of the interacting partner. As noted above, during preparatory sessions in drug-assisted psychotherapy the patient forms a bond with a therapists before the drug is administered, which may serve to increase the 'in-group' effect of the drug, and thus maximize the therapeutic potential of the MDMA.

Controlled laboratory studies (without psychotherapy) show that MDMA produces prosocial effects on measures of mood and socio-emotional function. However, most of these studies are conducted in isolated individuals, or with study partners who have no prior relationship with the participant. In this proposed study the study team will investigate whether the prosocial effects of MDMA are greater when interacting with a partner to whom the participant feels close and more connected, compared to a partner who is unfamiliar.

To establish familiarity in one of the study groups the study team will use a procedure designed to establish feelings of closeness and connectedness between two strangers. In this procedure, two same-sex partners, who are initially strangers, engage in a 45 min conversation with one of two sets of topics provided by the experimenter. In one condition the topics remain superficial ("small talk" condition) and in the other, they become progressively deeper ("deep talk" condition) over the 45 mins. The study team and others have shown that the deep talk condition produces feelings of connection between the partners, and participants report feeling understood and liking their partners.

In the present study, the investigator will use this procedure to establish familiarity between conversation partners. The investigator aims to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person. Participants will participate in four sessions, in which they receive MDMA (100 mg) or a placebo and then engage in a 15-min conversation with a familiar or unfamiliar person.

02

Conditions studied

  • MDMA ('Ecstasy')
  • Social Interaction
03

In context

Lead sponsor

University of Chicago is the lead sponsor of 907 studies on the registry; 182 are open to participants now.

Of its 99 completed or terminated interventional studies of FDA-regulated products, 68 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • used MDMA or psychedelic between 1-40
  • high school diploma or equivalent
  • BMI between 19 and 30
  • verbal fluency in English

Exclusion criteria

Exclusion Criteria:

  • History of adverse effects with MDMA
  • High blood pressure
  • Any medical condition requiring regular medication
  • Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
  • Women who are pregnant or trying to become pregnant.
05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Familiar partner with placebo

    Participant engages in social interaction with 'familiar' partner under placebo

    Drug: Placebo

  • Experimental
    Familiar partner with MDMA

    Participant engages in social interaction with 'familiar' partner under MDMA

    Drug: MDMA

  • Experimental
    Unfamiliar partner with placebo

    Participant engages in social interaction with 'unfamiliar' partner under placebo

    Drug: Placebo

  • Experimental
    Unfamiliar partner with MDMA

    Participant engages in social interaction with 'unfamiliar' partner under MDMA

    Drug: MDMA

Interventions

  • DrugMDMA

    The stimulant MDMA

  • DrugPlacebo

    Dextrose

06

What researchers measure

Primary outcomes

  1. Natural Language Processing using large language model

    Differences in speech content across all conditions

    Time frame: during 15 minute test conversation, occurring 1.5 hours after drug administration

  2. Facial expression analysis using HUMEAI software

    Changes in emotional expressions during conversations

    Time frame: during 15 minute test conversation, occurring 1.5 hours after drug administration

Secondary outcomes

  1. Oxytocin

    Changes in oxytocin levels across all conditions

    Time frame: 120 minutes post drug administration

  2. Self-reported feelings of connection using Likert scale conversation questionnaires

    ratings of connectedness

    Time frame: Collected at the end of the session, 240 minutes post-drug administration

  3. Affective touch

    Ratings of pleasantness, intensity and want more touch (1-7) after differing velocities of touch

    Time frame: Post-drug, 2 hours post-drug administration

07

Study locations

1 site
  • University of Chicago
    Chicago, Illinois 60637, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05948683
Lead sponsor
University of Chicago
Collaborators
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Jul 21, 2023
Primary completion
Jul 15, 2024
Completion
Jul 15, 2024
Last update
Aug 19, 2024

Study contacts

Harriet de Wit
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion